A Phase 1/2 interventional study of Futibatinib in Cholangiocarcinoma, Urothelial Cancer and Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, sponsored by Taiho Oncology, Inc.. Completed at 58 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 111 under way, 7 of them phase 3. Cholangiocarcinoma · United States.
Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 17th largest by enrollment of the 279 interventional ones that give a count, is one of 18 that started in 2014, is one of 42 in phase 1/2, and was the 58th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
328 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 127 · Phase 2 142 · Phase 3 24 · Phase 4 1
First in 2001; this study’s year is marked. 18 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 407 is above the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 44 across the 279 interventional studies, 230 across the 45 observational. Of the 190 that completed or were terminated, 94 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 328 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
Otsuka Holdings Co., Ltd. has 5 studies filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
36 of the studies in Cholangiocarcinoma with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05948475Phase 3TransThera Sciences (Nanjing), Inc.Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | 2026-12 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06723236MacroGenicsA Study of MGC028 in Participants With Advanced Solid Tumors | 2026-11 |
Add all 36 to your calendar (.ics) → With an account.
Among the 328 studies in Cholangiocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following specific criteria for each study portion
Phase 1 (Dose Escalation):
Phase 1 (Dose Expansion)
Patients with any of the following tumor types
Phase 2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with or without fibroblast growth factor \[FGF\]/fibroblast growth factor receptor \[FGFR\] gene abnormalities received orally TAS-120 8 milligrams (mg) orally every other day (QOD; Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with iCCA who were enrolled prior to the confirmation of the recommended Phase 2 dose (RP2D) received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
Drug: Futibatinib
oral once daily dosing, 21-day cycle
Also known as: TAS-120
Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)
MTD:Highest dose level at which \<33% of participants experience dose-limiting toxicity (DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.
Time frame: Cycle 1 (21-day cycle)
Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120
RP2D was MTD or less. MTD: Highest dose level at which \<33% of participants experience DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.
Time frame: Cycle 1 (21-day cycle)
Phase 1: Dose Expansion: Percentage of Participants With Objective Response
Objective response was defined as proportion of participants who had achieved best overall response of partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions. For Cohorts 1 to 6: Objective response was based on Independent Review Committee (IRC) and for pooled Sub-cohort: Objective response was based on investigator review.
Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts
Phase 2: Percentage of Participants With Objective Response
Objective response was defined as proportion of participants who had achieved best overall response of PR or CR per RECIST v1.1. CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 mm and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. The Phase 2 evaluation of objective response was based on central independent CT/MRI image assessment.
Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)
Phase 1: Dose Expansion: Duration of Response (DOR)
A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. For Cohorts 1 to 6: DOR was based on IRC and for Group 3, 4, 5, 6 and for pooled Sub-cohort: DOR was based on investigator review.
Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts
Phase 2: Duration of Response (DOR)
A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. Kaplan-Meier method was used for the analysis.
Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)
Phase 1: Dose Expansion: Disease Control Rate (DCR)
A DCR was defined as the proportion of participants with objective evidence of CR, PR, or stable disease (SD), except that there was no requirement for a confirmation of an SD, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. For Cohorts 1 to 6: DCR was based on IRC and for pooled Sub-cohort: DCR was based on investigator review.
Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohort
Phase 2: Disease Control Rate (DCR)
A DCR was defined as the proportion of participants with objective evidence of CR, PR, or SD, except that there was no requirement for a confirmation of an SD response, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. DCR was based on IRC.
Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)
Phase 1: Dose Expansion: Progression-free Survival (PFS)
A PFS was defined as the time (in months) from the day of the first dose to the date of first documented disease progression or death (due to any cause), whichever occurred first. Participants who died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS assessment per protocol was by IRC assessment for Cohorts 1 to 6 and for pooled Sub-cohort: PFS was based on investigator review.
Time frame: up to approximately 27.5 months (through cut-off date 30-Jun-2019)
Phase 2: Progression-free Survival (PFS)
A PFS was defined as the time (in months) from the day of the first dose to the date of first objectively documented disease progression or death (any cause), whichever occurred first. Participants who had died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS was analyzed as using Kaplan-Meier estimate.
Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)
Phase 1: Dose Expansion: Overall Survival (OS)
An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.
Time frame: up to approximately 27.5 months (through cut-off date 30-Jun-2019)
Phase 2: Overall Survival (OS)
An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.
Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Scores at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Self-care Scores at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Usual Activities Scores at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Pain/Discomfort Scores at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Anxiety/Depression Scores at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2: Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Specified Visits
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A vertical VAS allows the participants to indicate their health state that day, and ranged from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 2:Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score at Specified Timepoints
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 questions for evaluation of new chemotherapy \& assessment of participant reported outcome. EORTC QLQ-C30 included global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant.
Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Phase 1: Dose Expansion: Number of Participants With Any Adverse Events (AEs) and Any Serious AEs (SAEs)
An AE was defined as any untoward medical condition that occurred in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.
Time frame: From the first dose up to approximately 50.5 months (through cut-off date 29-May-2021)
Phase 2: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)
An AE was defined as any untoward medical condition that occurs in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.
Time frame: From the first dose up to approximately 37.5 months (through cut-off date 29-May-2021)
Study had Phase 1 and 2. Phase 1 included Dose escalation: 86 participants were enrolled \& treated and Dose Expansion: 284 participants were screened, of which 201 were enrolled; 197 were treated \& 4 were not treated. Phase 2: 120 participants signed informed consent, of which 17 were screen failures \& thus 103 were treated. In Participant Flow, Baseline Characteristics \& Adverse events, combined arm presentation of QOD \& QD dosing was made for Phase 1 Dose Escalation as pre-planned in protocol.
| Milestone | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1:Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 3 | 3 | 3 | 3 | 5 | 4 | 8 | 7 | 4 | 5 | 14 | 7 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 3 | 3 | 3 | 5 | 4 | 8 | 7 | 4 | 5 | 14 | 7 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Radiographic progression | 4 | 2 | 2 | 1 | 2 | 3 | 0 | 6 | 5 | 4 | 5 | 11 | 4 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical disease progression | 2 | 1 | 1 | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by participant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1:Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 35 | 16 | 13 | 25 | 27 | 19 | 8 | 0 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57 | 34 | 15 | 13 | 24 | 27 | 19 | 8 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 35 | 16 | 13 | 25 | 27 | 19 | 8 | 0 |
| Withdrew: Radiographic progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 23 | 12 | 11 | 17 | 21 | 14 | 6 | 0 |
| Withdrew: Clinical disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 0 | 2 | 3 | 4 | 5 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 3 | 0 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Untreated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1:Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 120 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 120 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Radiologic progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 78 |
| Withdrew: Clinical disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal by participant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Untreated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
MTD:Highest dose level at which \<33% of participants experience dose-limiting toxicity (DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.
| Milligrams | Phase 1: Dose Escalation: QOD Dosing | Phase 1: Dose Escalation: QD Dosing |
|---|---|---|
| Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) | NA | 20 |
RP2D was MTD or less. MTD: Highest dose level at which \<33% of participants experience DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.
| Milligrams | Phase 1: Dose Escalation: QOD Dosing | Phase 1: Dose Escalation: QD Dosing |
|---|---|---|
| Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120 | NA | 20 |
Objective response was defined as proportion of participants who had achieved best overall response of partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions. For Cohorts 1 to 6: Objective response was based on Independent Review Committee (IRC) and for pooled Sub-cohort: Objective response was based on investigator review.
| Percentage of participants | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Pooled Sub-cohort |
|---|---|---|---|---|---|---|---|
| Phase 1: Dose Expansion: Percentage of Participants With Objective Response | 15.8 (7.5 to 27.9) | 8.8 (1.9 to 23.7) | 13.3 (1.7 to 40.5) | 0 (0.0 to 24.7) | 12.5 (2.7 to 32.4) | 0 (0.0 to 12.8) | 33.3 (16.5 to 54.0) |
Objective response was defined as proportion of participants who had achieved best overall response of PR or CR per RECIST v1.1. CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 mm and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. The Phase 2 evaluation of objective response was based on central independent CT/MRI image assessment.
| Percentage of participants | Phase 2 |
|---|---|
| Phase 2: Percentage of Participants With Objective Response | 41.7 (32.1 to 51.9) |
A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. For Cohorts 1 to 6: DOR was based on IRC and for Group 3, 4, 5, 6 and for pooled Sub-cohort: DOR was based on investigator review.
| months | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Pooled Sub-cohort |
|---|---|---|---|---|---|---|---|
| Phase 1: Dose Expansion: Duration of Response (DOR) | 6.18 (2.8 to 10.6) | 3.52 (2.8 to 4.3) | 2.45 (1.4 to 3.4) | — | 2.79 (2.0 to 4.1) | — | 8.77 (3.5 to 20.8) |
A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. Kaplan-Meier method was used for the analysis.
| months | Phase 2 |
|---|---|
| Phase 2: Duration of Response (DOR) | 8.31 (2.1 to 24.8) |
A DCR was defined as the proportion of participants with objective evidence of CR, PR, or stable disease (SD), except that there was no requirement for a confirmation of an SD, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. For Cohorts 1 to 6: DCR was based on IRC and for pooled Sub-cohort: DCR was based on investigator review.
| Percentage of participants | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Pooled Sub-cohort |
|---|---|---|---|---|---|---|---|
| Phase 1: Dose Expansion: Disease Control Rate (DCR) | 66.7 (52.9 to 78.6) | 23.5 (10.7 to 41.2) | 33.3 (11.8 to 61.6) | 38.5 (13.9 to 68.4) | 54.2 (32.8 to 74.4) | 22.2 (8.6 to 42.3) | 66.7 (46.0 to 83.5) |
A DCR was defined as the proportion of participants with objective evidence of CR, PR, or SD, except that there was no requirement for a confirmation of an SD response, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. DCR was based on IRC.
| Percentage of participants | Phase 2 |
|---|---|
| Phase 2: Disease Control Rate (DCR) | 82.5 (73.8 to 89.3) |
A PFS was defined as the time (in months) from the day of the first dose to the date of first documented disease progression or death (due to any cause), whichever occurred first. Participants who died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS assessment per protocol was by IRC assessment for Cohorts 1 to 6 and for pooled Sub-cohort: PFS was based on investigator review.
| months | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Pooled Sub-cohort |
|---|---|---|---|---|---|---|---|
| Phase 1: Dose Expansion: Progression-free Survival (PFS) | 4.1 (2.7 to 6.9) | 1.9 (1.3 to 4.9) | 1.8 (1.3 to 4.7) | 1.3 (0.9 to 4.1) | 3.5 (1.7 to 6.8) | 2.7 (1.4 to 2.7) | 6.9 (4.6 to 10.8) |
A PFS was defined as the time (in months) from the day of the first dose to the date of first objectively documented disease progression or death (any cause), whichever occurred first. Participants who had died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS was analyzed as using Kaplan-Meier estimate.
| months | Phase 2 |
|---|---|
| Phase 2: Progression-free Survival (PFS) | 8.9 (6.7 to 11.0) |
An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.
| months | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Pooled Sub-cohort |
|---|---|---|---|---|---|---|---|
| Phase 1: Dose Expansion: Overall Survival (OS) | 11.4 (8.1 to 15.1) | 11.8 (5.5 to NA) | 8.6 (2.1 to NA) | 5.8 (4.6 to NA) | 10.5 (6.7 to NA) | 7.2 (5.6 to NA) | NA (12.2 to NA) |
An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.
| months | Phase 2 |
|---|---|
| Phase 2: Overall Survival (OS) | 20.0 (16.4 to 24.6) |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
| Participants | Phase 2 |
|---|---|
| Baseline — No Problem | 72 |
| Baseline — Some Problem | 18 |
| Baseline — Extreme Problem | 0 |
| Cycle 2 — No Problem | 60 |
| Cycle 2 — Some Problem | 20 |
| Cycle 2 — Extreme Problem | 1 |
| Cycle 4 — No Problem | 60 |
| Cycle 4 — Some Problem | 18 |
| Cycle 4 — Extreme Problem | 0 |
| Cycle 7 — No Problem | 51 |
| Cycle 7 — Some Problem | 14 |
| Cycle 7 — Extreme Problem | 0 |
| Cycle 10 — No Problem | 42 |
| Cycle 10 — Some Problem | 16 |
| Cycle 10 — Extreme Problem | 0 |
| Cycle 13 — No Problem | 32 |
| Cycle 13 — Some Problem | 15 |
| Cycle 13 — Extreme Problem | 0 |
| Cycle 16 — No Problem | 23 |
| Cycle 16 — Some Problem | 12 |
| Cycle 16 — Extreme Problem | 0 |
| Cycle 19 — No Problem | 16 |
| Cycle 19 — Some Problem | 12 |
| Cycle 19 — Extreme Problem | 0 |
| Cycle 22 — No Problem | 9 |
| Cycle 22 — Some Problem | 12 |
| Cycle 22 — Extreme Problem | 0 |
| Cycle 25 — No Problem | 9 |
| Cycle 25 — Some Problem | 2 |
| Cycle 25 — Extreme Problem | 1 |
| Cycle 28 — No Problem | 6 |
| Cycle 28 — Some Problem | 2 |
| Cycle 28 — Extreme Problem | 0 |
| Cycle 31 — No Problem | 3 |
| Cycle 31 — Some Problem | 0 |
| Cycle 31 — Extreme Problem | 0 |
| Cycle 34 — No Problem | 3 |
| Cycle 34 — Some Problem | 0 |
| Cycle 34 — Extreme Problem | 0 |
| Cycle 37 — No Problem | 2 |
| Cycle 37 — Some Problem | 1 |
| Cycle 37 — Extreme Problem | 0 |
| Cycle 40 — No Problem | 0 |
| Cycle 40 — Some Problem | 1 |
| Cycle 40 — Extreme Problem | 0 |
| End of Treatment — No Problem | 23 |
| End of Treatment — Some Problem | 20 |
| End of Treatment — Extreme Problem | 1 |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
| Participants | Phase 2 |
|---|---|
| Baseline — No Problem | 82 |
| Baseline — Some Problem | 8 |
| Baseline — Extreme Problem | 0 |
| Cycle 2 — No Problem | 75 |
| Cycle 2 — Some Problem | 6 |
| Cycle 2 — Extreme Problem | 0 |
| Cycle 4 — No Problem | 70 |
| Cycle 4 — Some Problem | 7 |
| Cycle 4 — Extreme Problem | 1 |
| Cycle 7 — No Problem | 58 |
| Cycle 7 — Some Problem | 6 |
| Cycle 7 — Extreme Problem | 1 |
| Cycle 10 — No Problem | 52 |
| Cycle 10 — Some Problem | 5 |
| Cycle 10 — Extreme Problem | 1 |
| Cycle 13 — No Problem | 41 |
| Cycle 13 — Some Problem | 6 |
| Cycle 13 — Extreme Problem | 0 |
| Cycle 16 — No Problem | 30 |
| Cycle 16 — Some Problem | 4 |
| Cycle 16 — Extreme Problem | 1 |
| Cycle 19 — No Problem | 22 |
| Cycle 19 — Some Problem | 6 |
| Cycle 19 — Extreme Problem | 0 |
| Cycle 22 — No Problem | 18 |
| Cycle 22 — Some Problem | 3 |
| Cycle 22 — Extreme Problem | 0 |
| Cycle 25 — No Problem | 9 |
| Cycle 25 — Some Problem | 3 |
| Cycle 25 — Extreme Problem | 0 |
| Cycle 28 — No Problem | 8 |
| Cycle 28 — Some Problem | 0 |
| Cycle 28 — Extreme Problem | 0 |
| Cycle 31 — No Problem | 3 |
| Cycle 31 — Some Problem | 0 |
| Cycle 31 — Extreme Problem | 0 |
| Cycle 34 — No Problem | 3 |
| Cycle 34 — Some Problem | 0 |
| Cycle 34 — Extreme Problem | 0 |
| Cycle 37 — No Problem | 2 |
| Cycle 37 — Some Problem | 1 |
| Cycle 37 — Extreme Problem | 0 |
| Cycle 40 — No Problem | 1 |
| Cycle 40 — Some Problem | 0 |
| Cycle 40 — Extreme Problem | 0 |
| End of Treatment — No Problem | 34 |
| End of Treatment — Some Problem | 8 |
| End of Treatment — Extreme Problem | 1 |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
| Participants | Phase 2 |
|---|---|
| Baseline — No Problem | 63 |
| Baseline — Some Problem | 24 |
| Baseline — Extreme Problem | 2 |
| Cycle 2 — No Problem | 47 |
| Cycle 2 — Some Problem | 32 |
| Cycle 2 — Extreme Problem | 2 |
| Cycle 4 — No Problem | 50 |
| Cycle 4 — Some Problem | 27 |
| Cycle 4 — Extreme Problem | 1 |
| Cycle 7 — No Problem | 43 |
| Cycle 7 — Some Problem | 20 |
| Cycle 7 — Extreme Problem | 2 |
| Cycle 10 — No Problem | 34 |
| Cycle 10 — Some Problem | 23 |
| Cycle 10 — Extreme Problem | 1 |
| Cycle 13 — No Problem | 28 |
| Cycle 13 — Some Problem | 19 |
| Cycle 13 — Extreme Problem | 0 |
| Cycle 16 — No Problem | 20 |
| Cycle 16 — Some Problem | 14 |
| Cycle 16 — Extreme Problem | 1 |
| Cycle 19 — No Problem | 15 |
| Cycle 19 — Some Problem | 12 |
| Cycle 19 — Extreme Problem | 1 |
| Cycle 22 — No Problem | 7 |
| Cycle 22 — Some Problem | 14 |
| Cycle 22 — Extreme Problem | 0 |
| Cycle 25 — No Problem | 4 |
| Cycle 25 — Some Problem | 7 |
| Cycle 25 — Extreme Problem | 1 |
| Cycle 28 — No Problem | 3 |
| Cycle 28 — Some Problem | 5 |
| Cycle 28 — Extreme Problem | 0 |
| Cycle 31 — No Problem | 1 |
| Cycle 31 — Some Problem | 2 |
| Cycle 31 — Extreme Problem | 0 |
| Cycle 34 — No Problem | 2 |
| Cycle 34 — Some Problem | 1 |
| Cycle 34 — Extreme Problem | 0 |
| Cycle 37 — No Problem | 0 |
| Cycle 37 — Some Problem | 3 |
| Cycle 37 — Extreme Problem | 0 |
| Cycle 40 — No Problem | 0 |
| Cycle 40 — Some Problem | 1 |
| Cycle 40 — Extreme Problem | 0 |
| End of Treatment — No Problem | 16 |
| End of Treatment — Some Problem | 25 |
| End of Treatment — Extreme Problem | 3 |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
| Participants | Phase 2 |
|---|---|
| Baseline — No Problem | 42 |
| Baseline — Some Problem | 47 |
| Baseline — Extreme Problem | 1 |
| Cycle 2 — No Problem | 45 |
| Cycle 2 — Some Problem | 35 |
| Cycle 2 — Extreme Problem | 1 |
| Cycle 4 — No Problem | 40 |
| Cycle 4 — Some Problem | 36 |
| Cycle 4 — Extreme Problem | 2 |
| Cycle 7 — No Problem | 36 |
| Cycle 7 — Some Problem | 29 |
| Cycle 7 — Extreme Problem | 1 |
| Cycle 10 — No Problem | 30 |
| Cycle 10 — Some Problem | 26 |
| Cycle 10 — Extreme Problem | 2 |
| Cycle 13 — No Problem | 23 |
| Cycle 13 — Some Problem | 22 |
| Cycle 13 — Extreme Problem | 2 |
| Cycle 16 — No Problem | 13 |
| Cycle 16 — Some Problem | 19 |
| Cycle 16 — Extreme Problem | 3 |
| Cycle 19 — No Problem | 13 |
| Cycle 19 — Some Problem | 15 |
| Cycle 19 — Extreme Problem | 0 |
| Cycle 22 — No Problem | 6 |
| Cycle 22 — Some Problem | 14 |
| Cycle 22 — Extreme Problem | 1 |
| Cycle 25 — No Problem | 3 |
| Cycle 25 — Some Problem | 9 |
| Cycle 25 — Extreme Problem | 0 |
| Cycle 28 — No Problem | 2 |
| Cycle 28 — Some Problem | 5 |
| Cycle 28 — Extreme Problem | 1 |
| Cycle 31 — No Problem | 2 |
| Cycle 31 — Some Problem | 1 |
| Cycle 31 — Extreme Problem | 0 |
| Cycle 34 — No Problem | 3 |
| Cycle 34 — Some Problem | 0 |
| Cycle 34 — Extreme Problem | 0 |
| Cycle 37 — No Problem | 2 |
| Cycle 37 — Some Problem | 1 |
| Cycle 37 — Extreme Problem | 0 |
| Cycle 40 — No Problem | 0 |
| Cycle 40 — Some Problem | 1 |
| Cycle 40 — Extreme Problem | 0 |
| End of Treatment — No Problem | 12 |
| End of Treatment — Some Problem | 27 |
| End of Treatment — Extreme Problem | 5 |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.
| Participants | Phase 2 |
|---|---|
| Baseline — No Problem | 64 |
| Baseline — Some Problem | 25 |
| Baseline — Extreme Problem | 0 |
| Cycle 2 — No Problem | 66 |
| Cycle 2 — Some Problem | 15 |
| Cycle 2 — Extreme Problem | 0 |
| Cycle 4 — No Problem | 63 |
| Cycle 4 — Some Problem | 14 |
| Cycle 4 — Extreme Problem | 1 |
| Cycle 7 — No Problem | 48 |
| Cycle 7 — Some Problem | 15 |
| Cycle 7 — Extreme Problem | 2 |
| Cycle 10 — No Problem | 44 |
| Cycle 10 — Some Problem | 12 |
| Cycle 10 — Extreme Problem | 2 |
| Cycle 13 — No Problem | 36 |
| Cycle 13 — Some Problem | 11 |
| Cycle 13 — Extreme Problem | 0 |
| Cycle 16 — No Problem | 26 |
| Cycle 16 — Some Problem | 8 |
| Cycle 16 — Extreme Problem | 1 |
| Cycle 19 — No Problem | 21 |
| Cycle 19 — Some Problem | 6 |
| Cycle 19 — Extreme Problem | 1 |
| Cycle 22 — No Problem | 13 |
| Cycle 22 — Some Problem | 8 |
| Cycle 22 — Extreme Problem | 0 |
| Cycle 25 — No Problem | 8 |
| Cycle 25 — Some Problem | 4 |
| Cycle 25 — Extreme Problem | 0 |
| Cycle 28 — No Problem | 5 |
| Cycle 28 — Some Problem | 3 |
| Cycle 28 — Extreme Problem | 0 |
| Cycle 31 — No Problem | 2 |
| Cycle 31 — Some Problem | 1 |
| Cycle 31 — Extreme Problem | 0 |
| Cycle 34 — No Problem | 2 |
| Cycle 34 — Some Problem | 1 |
| Cycle 34 — Extreme Problem | 0 |
| Cycle 37 — No Problem | 1 |
| Cycle 37 — Some Problem | 2 |
| Cycle 37 — Extreme Problem | 0 |
| Cycle 40 — No Problem | 0 |
| Cycle 40 — Some Problem | 1 |
| Cycle 40 — Extreme Problem | 0 |
| End of Treatment — No Problem | 22 |
| End of Treatment — Some Problem | 19 |
| End of Treatment — Extreme Problem | 3 |
EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A vertical VAS allows the participants to indicate their health state that day, and ranged from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.
| score on a scale | Phase 2 |
|---|---|
| Baseline | 71.72 ± 20.307 |
| Change at Cycle 2 | -0.73 ± 19.409 |
| Change at Cycle 4 | -1.04 ± 23.984 |
| Change at Cycle 7 | -1.82 ± 29.984 |
| Change at Cycle 10 | 0.40 ± 30.428 |
| Change at Cycle 13 | 4.76 ± 26.585 |
| Change at Cycle 16 | -1.71 ± 34.417 |
| Change at Cycle 19 | 1.76 ± 25.155 |
| Change at Cycle 22 | 1.85 ± 31.707 |
| Change at Cycle 25 | -0.82 ± 45.828 |
| Change at Cycle 28 | -1.85 ± 40.912 |
| Change at Cycle 31 | 18.17 ± 17.280 |
| Change at Cycle 34 | 19.00 ± 19.313 |
| Change at Cycle 37 | 15.17 ± 21.624 |
| Change at Cycle 40 | 15.00 |
| End of Treatment | -8.89 ± 26.272 |
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 questions for evaluation of new chemotherapy \& assessment of participant reported outcome. EORTC QLQ-C30 included global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant.
| score on scale | Phase 2 |
|---|---|
| Baseline | 70.1 ± 19.41 |
| Change at Cycle 2 | -1.0 ± 22.02 |
| Change at Cycle 4 | 0.4 ± 20.62 |
| Change at Cycle 7 | -0.5 ± 21.64 |
| Change at Cycle 10 | 1.9 ± 22.84 |
| Change at Cycle 13 | 0.9 ± 21.49 |
| Change at Cycle 16 | 2.5 ± 18.61 |
| Change at Cycle 19 | -1.7 ± 17.31 |
| Change at Cycle 22 | -8.3 ± 22.05 |
| Change at Cycle 25 | -4.8 ± 21.44 |
| Change at Cycle 28 | -6.3 ± 12.50 |
| Change at Cycle 31 | 41.7 |
| Change at Cycle 34 | 41.7 |
| End of Treatment | -7.5 ± 23.30 |
An AE was defined as any untoward medical condition that occurred in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.
| Participants | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 |
|---|---|---|---|---|---|---|---|---|
| AEs | 57 | 34 | 15 | 13 | 23 | 26 | 18 | 5 |
| SAEs | 27 | 13 | 10 | 9 | 13 | 14 | 0 | 0 |
An AE was defined as any untoward medical condition that occurs in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.
| Participants | Phase 2 |
|---|---|
| AEs | 103 |
| SAEs | 42 |
Collected over From the first dose administration up to approximately up to 59.5 months for Phase 1 Dose escalation; up to 50.5 months for Phase 1 Dose expansion Cohorts and up to 37.5 months for Phase 2. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Dose Escalation: QOD Dosing: 8 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 16 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 24 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 36 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 56 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 80 mg | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 120 mg | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 160 mg | 0/8 (0%) | 7/8 (87.5%) | 8/8 (100%) |
| Phase 1: Dose Escalation: QOD Dosing: 200 mg | 2/7 (28.6%) | 4/7 (57.1%) | 7/7 (100%) |
| Phase 1: Dose Escalation: QD Dosing: 4 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Phase 1: Dose Escalation: QD Dosing: 8 mg | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Phase 1: Dose Escalation: QD Dosing: 16 mg | 2/14 (14.3%) | 9/14 (64.3%) | 14/14 (100%) |
| Phase 1: Dose Escalation: QD Dosing: 20 mg | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Phase 1: Dose Escalation: QD Dosing: 24 mg | 1/14 (7.1%) | 6/14 (42.9%) | 14/14 (100%) |
| Phase 1: Dose Expansion Cohort 1 | 40/57 (70.2%) | 27/57 (47.4%) | 57/57 (100%) |
| Phase 1: Dose Expansion: Cohort 2 | 22/34 (64.7%) | 13/34 (38.2%) | 34/34 (100%) |
| Phase 1: Dose Expansion: Cohort 3 | 12/15 (80%) | 10/15 (66.7%) | 15/15 (100%) |
| Phase 1: Dose Expansion: Cohort 4 | 11/13 (84.6%) | 9/13 (69.2%) | 13/13 (100%) |
| Phase 1: Dose Expansion: Cohort 5 | 15/24 (62.5%) | 13/24 (54.2%) | 23/24 (95.8%) |
| Phase 1: Dose Expansion: Cohort 6 | 17/27 (63%) | 14/27 (51.9%) | 26/27 (96.3%) |
| Phase 1: Dose Expansion: Sub-cohort 2 | 1/8 (12.5%) | 0/8 (0%) | 8/8 (100%) |
| Phase 1: Dose Expansion: Sub-cohort 1 | 9/19 (47.4%) | 0/19 (0%) | 19/19 (100%) |
| Phase 2 | 58/103 (56.3%) | 42/103 (40.8%) | 103/103 (100%) |
| Event | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/3 | 1/3 | 0/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 0/14 | 1/57 | 0/34 | 0/15 | 0/13 | 0/24 | 1/27 | 0/8 | 0/19 | 1/103 |
| PyrexiaGeneral disorders | 0/6 | 0/3 | 0/3 | 0/3 | 1/3 | 0/5 | 0/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 1/14 | 1/57 | 0/34 | 0/15 | 0/13 | 0/24 | 1/27 | 0/8 | 0/19 | 4/103 |
| CellulitisInfections and infestations | 0/6 | 0/3 | 1/3 | 0/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 1/14 | 0/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 1/103 |
| PneumoniaInfections and infestations | 0/6 | 0/3 | 0/3 | 1/3 | 0/3 | 1/5 | 0/4 | 1/8 | 0/7 | 0/4 | 0/5 | 0/14 | 1/7 | 0/14 | 0/57 | 0/34 | 0/15 | 0/13 | 0/24 | 1/27 | 0/8 | 0/19 | 1/103 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/6 | 0/3 | 0/3 | 1/3 | 0/3 | 0/5 | 1/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 0/14 | 1/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 1/103 |
| Disease progressionGeneral disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/5 | 0/4 | 0/8 | 1/7 | 0/4 | 0/5 | 1/14 | 2/7 | 1/14 | 2/57 | 0/34 | 3/15 | 2/13 | 0/24 | 1/27 | 0/8 | 0/19 | 5/103 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/5 | 0/4 | 2/8 | 1/7 | 0/4 | 0/5 | 1/14 | 0/7 | 0/14 | 3/57 | 0/34 | 0/15 | 1/13 | 1/24 | 0/27 | 0/8 | 0/19 | 1/103 |
| NauseaGastrointestinal disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/5 | 1/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 1/7 | 1/14 | 1/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 1/103 |
| VomitingGastrointestinal disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/5 | 1/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 1/7 | 1/14 | 1/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 1/103 |
| HemiparesisNervous system disorders | 0/6 | 0/3 | 0/3 | 0/3 | 0/3 | 0/5 | 1/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 0/14 | 0/57 | 2/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 0/103 |
| Event | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/6 | 3/3 | 1/3 | 0/3 | 1/3 | 1/5 | 2/4 | 6/8 | 3/7 | 0/4 | 0/5 | 5/14 | 3/7 | 7/14 | 17/57 | 13/34 | 4/15 | 3/13 | 11/24 | 10/27 | 5/8 | 5/19 | 37/103 |
| HyperphosphataemiaMetabolism and nutrition disorders | 0/6 | 1/3 | 1/3 | 0/3 | 0/3 | 4/5 | 3/4 | 6/8 | 6/7 | 1/4 | 2/5 | 9/14 | 6/7 | 12/14 | 48/57 | 30/34 | 9/15 | 12/13 | 19/24 | 21/27 | 5/8 | 17/19 | 88/103 |
| Dry mouthGastrointestinal disorders | 2/6 | 0/3 | 1/3 | 2/3 | 0/3 | 1/5 | 3/4 | 3/8 | 2/7 | 2/4 | 1/5 | 4/14 | 1/7 | 3/14 | 13/57 | 4/34 | 3/15 | 1/13 | 3/24 | 7/27 | 0/8 | 7/19 | 36/103 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 1/3 | 0/3 | 2/3 | 0/3 | 0/5 | 0/4 | 0/8 | 0/7 | 1/4 | 0/5 | 1/14 | 1/7 | 0/14 | 4/57 | 2/34 | 0/15 | 0/13 | 0/24 | 3/27 | 0/8 | 3/19 | 8/103 |
| AstheniaGeneral disorders | 1/6 | 2/3 | 0/3 | 1/3 | 1/3 | 1/5 | 0/4 | 2/8 | 1/7 | 1/4 | 1/5 | 4/14 | 1/7 | 2/14 | 7/57 | 7/34 | 2/15 | 0/13 | 4/24 | 6/27 | 1/8 | 1/19 | 4/103 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 1/3 | 0/3 | 2/3 | 0/3 | 0/5 | 1/4 | 3/8 | 2/7 | 1/4 | 2/5 | 1/14 | 0/7 | 3/14 | 10/57 | 6/34 | 4/15 | 1/13 | 7/24 | 6/27 | 1/8 | 3/19 | 23/103 |
| PruritusSkin and subcutaneous tissue disorders | 1/6 | 0/3 | 0/3 | 0/3 | 2/3 | 0/5 | 0/4 | 1/8 | 0/7 | 1/4 | 0/5 | 0/14 | 0/7 | 0/14 | 3/57 | 1/34 | 0/15 | 0/13 | 1/24 | 2/27 | 0/8 | 1/19 | 9/103 |
| Lipase increasedInvestigations | 0/6 | 0/3 | 0/3 | 0/3 | 2/3 | 0/5 | 0/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 0/14 | 0/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 0/103 |
| Platelet count increasedInvestigations | 0/6 | 0/3 | 0/3 | 0/3 | 2/3 | 0/5 | 0/4 | 0/8 | 0/7 | 0/4 | 0/5 | 0/14 | 0/7 | 0/14 | 0/57 | 0/34 | 0/15 | 0/13 | 0/24 | 0/27 | 0/8 | 0/19 | 0/103 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 0/3 | 0/3 | 1/3 | 1/3 | 1/5 | 2/4 | 4/8 | 1/7 | 1/4 | 0/5 | 2/14 | 3/7 | 3/14 | 10/57 | 4/34 | 2/15 | 3/13 | 4/24 | 5/27 | 1/8 | 2/19 | 17/103 |
Analysis was performed on all treated population.
| Age, Categorical(Participants) | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 2 | 2 | 2 | 3 | 1 | 6 | 5 | 3 | 3 | 12 | 4 | 11 | 45 | 27 | 5 | 10 | 21 | 18 | 18 | 6 | 80 | 290 |
| >=65 years | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 3 | 3 | 12 | 7 | 10 | 3 | 3 | 9 | 1 | 2 | 23 | 96 |
| Sex: Female, Male(Participants) | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 2 | 2 | 0 | 4 | 1 | 4 | 5 | 2 | 0 | 8 | 6 | 13 | 40 | 12 | 4 | 9 | 14 | 16 | 14 | 7 | 58 | 226 |
| Male | 2 | 2 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 5 | 6 | 1 | 1 | 17 | 22 | 11 | 4 | 10 | 11 | 5 | 1 | 45 | 160 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 9 |
| Not Hispanic or Latino | 6 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 3 | 7 | 6 | 6 | 41 | 19 | 7 | 13 | 16 | 23 | 18 | 5 | 89 | 281 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 5 | 4 | 2 | 2 | 7 | 1 | 7 | 14 | 15 | 8 | 0 | 8 | 3 | 0 | 1 | 12 | 96 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Dose Escalation: QOD Dosing: 8 mg | Phase 1: Dose Escalation: QOD Dosing: 16 mg | Phase 1: Dose Escalation: QOD Dosing: 24 mg | Phase 1: Dose Escalation: QOD Dosing: 36 mg | Phase 1: Dose Escalation: QOD Dosing: 56 mg | Phase 1: Dose Escalation: QOD Dosing: 80 mg | Phase 1: Dose Escalation: QOD Dosing: 120 mg | Phase 1: Dose Escalation: QOD Dosing: 160 mg | Phase 1: Dose Escalation: QOD Dosing: 200 mg | Phase 1: Dose Escalation: QD Dosing: 4 mg | Phase 1: Dose Escalation: QD Dosing: 8 mg | Phase 1: Dose Escalation: QD Dosing: 16 mg | Phase 1: Dose Escalation: QD Dosing: 20 mg | Phase 1: Dose Escalation: QD Dosing: 24 mg | Phase 1: Dose Expansion Cohort 1 | Phase 1: Dose Expansion: Cohort 2 | Phase 1: Dose Expansion: Cohort 3 | Phase 1: Dose Expansion: Cohort 4 | Phase 1: Dose Expansion: Cohort 5 | Phase 1: Dose Expansion: Cohort 6 | Phase 1: Dose Expansion: Sub-cohort 1 | Phase 1: Dose Expansion: Sub-cohort 2 | Phase 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian/Oriental | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 2 | 0 | 8 | 3 | 2 | 1 | 0 | 30 | 55 |
| White/Caucasian | 6 | 3 | 3 | 3 | 2 | 1 | 3 | 5 | 5 | 3 | 4 | 7 | 6 | 8 | 37 | 17 | 7 | 2 | 15 | 22 | 16 | 7 | 51 | 233 |
| Black or African-American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 8 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Missing/Unknown | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 3 | 2 | 1 | 0 | 7 | 0 | 4 | 13 | 15 | 8 | 0 | 6 | 2 | 1 | 1 | 13 | 81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2014 to primary completion in Oct 2020, 74 months.
Results were first posted in Mar 2024, 3 years 5 months after primary completion. A results delay was requested in Sep 2021.
Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's 74 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Futibatinib